Scarica l'app Stockscreener
10.90
3.63%
-0.41
Dopo l'orario di chiusura:
10.90
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NEO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.31
Aprire:
$11.24
Volume 24 ore:
1.05M
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.42B
Reddito:
$745.97M
Utile/perdita netta:
$-99.21M
Rapporto P/E:
-14.10
EPS:
-0.7729
Flusso di cassa netto:
$-5.09M
1 W Prestazione:
+3.61%
1M Prestazione:
+23.02%
6M Prestazione:
-8.40%
1 anno Prestazione:
+52.88%
Intervallo 1D:
$10.70
$11.44
Intervallo di 1 settimana:
$9.895
$11.57
Portata 52W:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Nome
Neogenomics Inc
Settore
Industria
Telefono
(239) 768-0600
Indirizzo
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
10.90 | 1.47B | 745.97M | -99.21M | -5.09M | -0.7729 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-07-29 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Iniziato | Guggenheim | Neutral |
| 2025-04-30 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Iniziato | Jefferies | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-08-21 | Aggiornamento | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2023-02-24 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Aggiornamento | Needham | Hold → Buy |
| 2022-08-26 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Downgrade | Needham | Buy → Hold |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-03-29 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-29 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Ripresa | Stephens | Overweight |
| 2021-12-16 | Iniziato | Cowen | Outperform |
| 2021-11-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-02-25 | Ripresa | Needham | Buy |
| 2021-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-12-11 | Ripresa | BTIG Research | Buy |
| 2020-10-28 | Reiterato | Needham | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-28 | Iniziato | Guggenheim | Buy |
| 2020-07-29 | Reiterato | Needham | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Buy |
| 2020-04-21 | Ripresa | Stephens | Overweight |
| 2020-03-02 | Ripresa | Craig Hallum | Buy |
| 2020-02-28 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Reiterato | Needham | Buy |
| 2019-05-01 | Reiterato | Needham | Buy |
| 2019-03-29 | Reiterato | Needham | Buy |
| 2019-01-03 | Iniziato | Needham | Buy |
| 2018-10-24 | Aggiornamento | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Iniziato | Leerink Partners | Outperform |
| 2018-05-02 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2017-08-24 | Iniziato | Gabelli & Co | Buy |
| 2016-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Neogenomics Inc Borsa (NEO) Ultime notizie
NeoGenomics (NEO) Q1 2025 Earnings Transcript - AOL.com
(NEO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
NeoGenomics (NEO) director gains RSU grants and stock options, exercises awards - Stock Titan
Felicia Williams (NASDAQ: NEO) gains shares via RSUs and options - Stock Titan
NeoGenomics (NEO) director boosts holdings through option and RSU awards - Stock Titan
NeoGenomics (NASDAQ: NEO) director exercises RSUs and gains new options - Stock Titan
NeoGenomics (NEO) director adds shares via RSU release and new options - Stock Titan
NeoGenomics (NEO) director exercises 23,077 RSUs and receives new option, RSU grants - Stock Titan
NeoGenomics (NEO) director adds 23,077 shares through RSU vesting - Stock Titan
NeoGenomics (NEO) director reports RSU release and new stock option grants - Stock Titan
NeoGenomics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 6, 2023 to Discuss Your RightsNEO - TMX Newsfile
NeoGenomics Inc (NEO) Stock Up 6.5% and Still Undervalued -- GF Score: 68/100 - GuruFocus
William Blair Maintains NeoGenomics(NEO.US) With Hold Rating - Moomoo
Is NeoGenomics (NEO) Using Its ASCO ctDNA Focus To Redefine Its Precision Oncology Edge? - Yahoo Finance
NeoGenomics to Present New Research at ASCO Annual Meeting 2026 - Business Wire
(NEO) Risk Channels and Responsive Allocation - Stock Traders Daily
NeoGenomics Investor Alert - TMX Newsfile
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $11 to $25 - Moomoo
Shareholders approve NeoGenomics (NASDAQ: NEO) equity plan amendment and board slate - Stock Titan
NeoGenomics Earnings Call Highlights NGS-Driven Momentum - TipRanks
NeoGenomics stock (US64049M2098): Q1 update keeps focus on cancer testing demand - AD HOC NEWS
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance
NEOGENOMICS (NEO) 13G/A: Greenhouse reports 9,215,903 shares (7.1%) - Stock Titan
NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN
Oncology diagnostics group NeoGenomics meets investors at May, June conferences - Stock Titan
NeoGenomics to Participate in Upcoming Investor Conferences - The Joplin Globe
(NEO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
This NeoGenomics Insider Reduced Their Stake By 15% - Moomoo
Millennium group reports 2.22M NEO shares (1.7%) — Joint filing (NEO) - Stock Titan
NeoGenomics (NEO) EVP adds shares via RSU vesting while covering taxes - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, withholds shares for taxes and holds 164,032 shares - Stock Titan
TradingKey - TradingKey
Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO? - Sahm
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
NeoGenomics Inc. (NEO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NeoGenomics to Host Second Quarter 2015 Earnings Conference Call and Webcast Live on Thursday, July 23, 2015 - ACCESS Newswire
NEO PE Ratio & Valuation, Is NEO Overvalued - Intellectia AI
First Light, Mathew Arens report 10.8% stakes in Neogenomics (NEO) - Stock Titan
NeoGenomics (NEO) Q1 2026 Earnings Transcript - AOL.com
NEO SEC FilingsNeogenomics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
NeoGenomics shares jump on earnings and analyst upgrades - MSN
NeoGenomics (NEO) CAO exercises RSUs, surrenders shares for taxes - Stock Titan
NeoGenomics (NEO) EVP updates equity awards, reports tax-withholding share move - Stock Titan
NeoGenomics (NEO) COO exercises RSUs, shares withheld for tax - Stock Titan
MSN Money - MSN
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call - The Globe and Mail
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Liquidity Mapping Around (NEO) Price Events - Stock Traders Daily
NeoGenomics (NEO) Is Up 13.9% After Strong Q1 Revenue And New Epic Aura Integration - simplywall.st
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Opus Genetics (IRD), NeoGenomics (NEO) and Teladoc (TDOC) - The Globe and Mail
A Look At NeoGenomics (NEO) Valuation After Q1 2026 Results And Epic Aura Oncology Integration - Yahoo Finance
Neogenomics Inc Azioni (NEO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neogenomics Inc Azioni (NEO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Williams Felicia | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
23,077 |
0 |
30,237 |
| TETRAULT LYNN A. | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
23,077 |
0 |
96,729 |
| Perez David Brian | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
23,077 |
0 |
56,967 |
| Kelly Michael Aaron | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
23,077 |
0 |
67,086 |
| KANOVSKY STEPHEN M | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
23,077 |
0 |
75,421 |
| Gunn Neil | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
23,077 |
0 |
51,177 |
| Green Marjorie C | Director |
Jun 01 '26 |
Option Exercise |
0.00 |
22,964 |
0 |
22,964 |
| Olivo Alicia C | EVP, GC & Business Development |
May 11 '26 |
Option Exercise |
0.00 |
3,944 |
0 |
96,126 |
| Stone Warren | Pres & Chief Operating Officer |
May 11 '26 |
Option Exercise |
0.00 |
5,830 |
0 |
167,815 |
| Aunan Greg D | Chief Accounting Officer |
May 02 '26 |
Option Exercise |
0.00 |
5,372 |
0 |
26,462 |
2.13%
2.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):